Drug Trial Radar · NCT06622486
First-in-human Trial of EGL-001 in Patients with Selected Advanced And/or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 7, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Sep 27, 2024
Primary completion
Jan 23, 2027
Study completion Jan 23, 2027
Sponsor
- Lead sponsor
- Egle TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This multicenter, open-label, first-in-human, Phase 1/2 study consists of a Part 1 (Phase 1) open-label dose escalation of EGL-001 administered as a single agent and in combination with an anti-PD(L)-1 treatment, followed by a Part 2 (Phase 2) open-label dose expansion of EGL-001 administered at the RP2D in patients with recurrent and/or metastatic solid tumors as monotherapy and/or combination therapy with anti-PD(L)-1.
Conditions
- Solid Tumor, Adult
Interventions
EGL-001Drug
IV administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
- To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
- To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
- To evaluate the safety, tolerability, dose-limiting toxicities (DLTs) and the maximum tolerated dose (MTD) leading to the recommended Phase 2 doses (RP2Ds)Time frame: Day 1 up to 90 days after last dose
Locations
8 sites in 2 countries. Site status is shown where the registry gives one.
Centr Georges Francois Leclerc
Dijon, France · Not yet recruiting
Institut Regional Du Cancer De Montpellier
Montpellier, France · Recruiting
Institut Curie
Paris, France · Recruiting
Institut Gustave Roussy
Paris, France · Not yet recruiting
Hospital Universitari Vall D Hebron
Barcelona, Spain · Not yet recruiting
Hospital Universitario Fundacion Jimenez Diaz
Madrid, Spain · Not yet recruiting
Clinica Universidad De Navarra
Pamplona, Spain · Not yet recruiting
Hospital Clinico Universitario De Valencia
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.